Targeting the VEGF-VEGFR system, PTK787, an orally effective selective VEGFR inhibitor, obviously limited angiogenesis and brain metastasis growth and increased apoptosis in tumor cells in preclinical models (Figure 1). Here, VEGFA is linked to neoplasm.